Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)
China · Delayed Price · Currency is CNY 33.50
-0.95 (-2.76%)
At close: Jan 28, 2026
SHE:301263 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 673.63 | 720.17 | 760.07 | 782.8 | 653.65 | 708.98 |
Other Revenue | 0.86 | 0.86 | 0.72 | 0.68 | - | - |
| 674.49 | 721.03 | 760.79 | 783.48 | 653.65 | 708.98 | |
Revenue Growth (YoY) | -10.32% | -5.23% | -2.90% | 19.86% | -7.80% | 42.83% |
Cost of Revenue | 331.63 | 319.09 | 303.93 | 328.67 | 326.37 | 320.69 |
Gross Profit | 342.86 | 401.94 | 456.85 | 454.81 | 327.28 | 388.29 |
Selling, General & Admin | 263.8 | 203.97 | 202.59 | 211.83 | 163.4 | 150.48 |
Research & Development | 79.06 | 86.42 | 62.89 | 40.39 | 26.46 | 31.34 |
Other Operating Expenses | 3 | 1.73 | 3.78 | 4.35 | 7.08 | 7.82 |
Operating Expenses | 344.51 | 291.88 | 273.14 | 260.03 | 199.77 | 196.45 |
Operating Income | -1.65 | 110.06 | 183.71 | 194.78 | 127.5 | 191.84 |
Interest Expense | -9.45 | -8.63 | -1.7 | -2.58 | -4.72 | -5.14 |
Interest & Investment Income | 3.66 | 9.51 | 16.48 | 19.13 | 0.87 | 1.11 |
Currency Exchange Gain (Loss) | -2.3 | -2.3 | -0.88 | -4.34 | 0.53 | 0.43 |
Other Non Operating Income (Expenses) | 3.34 | -0.16 | -0.12 | -0.11 | -0.25 | -0.4 |
EBT Excluding Unusual Items | -6.41 | 108.48 | 197.49 | 206.88 | 123.93 | 187.84 |
Gain (Loss) on Sale of Investments | 0.31 | 0.1 | 0.8 | 0.65 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | - | 0.15 | 0.01 | -0.02 | -0.51 |
Asset Writedown | 0.66 | -1.27 | -7.61 | -0.3 | -0.5 | -1.3 |
Other Unusual Items | -1.74 | -1.74 | 1.5 | 0.12 | 14.14 | 11.52 |
Pretax Income | -7.17 | 105.57 | 192.32 | 207.35 | 137.54 | 197.55 |
Income Tax Expense | -21.15 | 8.53 | 38.82 | 32.75 | 17.55 | 43.85 |
Earnings From Continuing Operations | 13.99 | 97.04 | 153.5 | 174.6 | 120 | 153.7 |
Minority Interest in Earnings | 9.3 | 11.18 | 6.7 | 0.01 | 0.07 | 7.12 |
Net Income | 23.29 | 108.22 | 160.2 | 174.61 | 120.07 | 160.83 |
Net Income to Common | 23.29 | 108.22 | 160.2 | 174.61 | 120.07 | 160.83 |
Net Income Growth | -82.71% | -32.45% | -8.25% | 45.43% | -25.34% | 192.92% |
Shares Outstanding (Basic) | 430 | 416 | 422 | 397 | 318 | 298 |
Shares Outstanding (Diluted) | 430 | 416 | 422 | 397 | 318 | 298 |
Shares Change (YoY) | 1.69% | -1.27% | 6.23% | 24.87% | 6.49% | 5.67% |
EPS (Basic) | 0.05 | 0.26 | 0.38 | 0.44 | 0.38 | 0.54 |
EPS (Diluted) | 0.05 | 0.26 | 0.38 | 0.44 | 0.38 | 0.54 |
EPS Growth | -83.00% | -31.58% | -13.64% | 16.46% | -29.89% | 177.21% |
Free Cash Flow | -63.42 | 20.78 | -106.48 | 58.94 | 75.38 | 32.41 |
Free Cash Flow Per Share | -0.15 | 0.05 | -0.25 | 0.15 | 0.24 | 0.11 |
Dividend Per Share | 0.200 | 0.200 | 0.300 | 0.389 | 0.194 | - |
Dividend Growth | -33.33% | -33.33% | -22.86% | 100.05% | - | - |
Gross Margin | 50.83% | 55.74% | 60.05% | 58.05% | 50.07% | 54.77% |
Operating Margin | -0.24% | 15.26% | 24.15% | 24.86% | 19.51% | 27.06% |
Profit Margin | 3.45% | 15.01% | 21.06% | 22.29% | 18.37% | 22.68% |
Free Cash Flow Margin | -9.40% | 2.88% | -14.00% | 7.52% | 11.53% | 4.57% |
EBITDA | 62.08 | 162.46 | 221.01 | 226.75 | 155.09 | 214.49 |
EBITDA Margin | 9.20% | 22.53% | 29.05% | 28.94% | 23.73% | 30.25% |
D&A For EBITDA | 63.73 | 52.4 | 37.3 | 31.97 | 27.58 | 22.65 |
EBIT | -1.65 | 110.06 | 183.71 | 194.78 | 127.5 | 191.84 |
EBIT Margin | -0.24% | 15.26% | 24.15% | 24.86% | 19.51% | 27.06% |
Effective Tax Rate | - | 8.08% | 20.19% | 15.79% | 12.76% | 22.20% |
Revenue as Reported | 674.49 | 721.03 | 760.79 | 783.48 | 653.65 | 708.98 |
Advertising Expenses | - | 65.86 | 71.69 | 95.69 | 61.51 | 44.68 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.